

## United States Patent and Trademark Office

UNITED STATE SUPEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/769,404	01/26/2001	Theo Wallimann	8932-296	4809
20582 JONES DAY	7590 07/13/2007		EXAM	INER
222 East 41st Street			WANG, SHENGJUN	
New York, NY 10017-6702		•	ART UNIT	PAPER NUMBER
		•	1617	
			MAIL DATE	DELIVERY MODE
·	Y	•	07/13/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)		
Office Action Summary		. 09/769,404	WALLIMANN ET AL.		
		Examiner	Art Unit		
		Shengjun Wang	1617		
	The MAILING DATE of this communication app		vith the correspondence address		
Period fo	• •				
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPL' CHEVER IS LONGER, FROM THE MAILING D. Insions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. In period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNI 36(a). In no event, however, may a will apply and will expire SIX (6) MO e, cause the application to become A	ICATION. I reply be timely filed INTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).		
Status	·				
1)⊠	Responsive to communication(s) filed on 17 A	pril 2007.			
2a) <u></u> ☐	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.				
3)[	Since this application is in condition for allowa	•	,		
	closed in accordance with the practice under E	Ex parte Quayle, 1935 C.Γ	J. 11, 453 O.G. 213.		
Dispositi	ion of Claims				
4)🖂	Claim(s) 23,24 and 31-41 is/are pending in the	application.			
	4a) Of the above claim(s) is/are withdraw	wn from consideration.			
5)	Claim(s) is/are allowed.				
	Claim(s) <u>23,24 and 31-41</u> is/are rejected.				
	Claim(s) is/are objected to.				
8)	Claim(s) are subject to restriction and/o	r election requirement.			
Applicati	ion Papers				
9)[	The specification is objected to by the Examine	er.			
10)	The drawing(s) filed on is/are: a) acc	epted or b)⊡ objected to	by the Examiner.		
	Applicant may not request that any objection to the	drawing(s) be held in abeya	ince. See 37 CFR 1.85(a).		
	Replacement drawing sheet(s) including the correct				
11)	The oath or declaration is objected to by the Ex	kaminer. Note the attache	d Office Action or form PTO-152.		
Priority ι	ınder 35 U.S.C. § 119				
-	Acknowledgment is made of a claim for foreign  ☐ All b) ☐ Some * c) ☐ None of:	priority under 35 U.S.C.	§ 119(a)-(d) or (f).		
	1. Certified copies of the priority document	s have been received.			
	2. Certified copies of the priority document		<u> </u>		
	3. Copies of the certified copies of the prior	•	n received in this National Stage		
* 0	application from the International Bureau		A managinard		
	See the attached detailed Office action for a list	or the certified copies not	received.		
Attachmen	• •	o□	Output (DTO 440)		
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)		Summary (PTO-413) (s)/Mail Date		
3) 🔲 Infor	nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	5)  Notice of 6)  Other:	Informal Patent Application		

Application/Control Number: 09/769,404 Page 2

Art Unit: 1617

## **DETAILED ACTION**

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on APRIL 17, 2007 has been entered.

## Claim Rejections 35 U.S.C. 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. Claims 23-41 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kaddurah-Daouk (US 5,998,457) in view of Meisner (US 4,772,591), Grant et al. (US 5,888,553), Beale (US 5,756,469) and Beale (US 5,716,926).
- 3. Kaddurah-Daouk teaches a method of treating osteoporosis or osteoarthritis comprising administering therapeutical effective amount of creatine compound, or a pharmaceutical acceptable salt, to patient. See, particularly, the abstract, table 1-2, and claims 1-12. As to the amount of creatine administered, Kaddurah-Daouk states: "the actual amount of drug needed will be depend on factors such as the size, age, and severity of disease in afflicted individual. ... for this invention the creatine compound will be administered at dosage and period of time effective to reduce, ameliorate or eliminate the symptoms of the disease." Col. 11, lines 24-44.

Application/Control Number: 09/769,404

Art Unit: 1617

4. Kaddurah-Daouk does not teach expressly the employment of creatine pyruvate for the treatment, or the particular amount administered, or the method may be employed for promoting growth and mineralization of bone; improving acceptance and osseous integration of bone; or accelerating healing as claimed herein, or the purity as herein required.

Page 3

5. However, Grant et al. teaches that the excess of cortisol is known to be a cause of osteoporosis, tissue degeneration, and an anabolic composition with anticortisol effect are used to balance effect of cortisol. The anabolic composition comprising creatine or its salts, wherein the amount of creatine or its salts is in the range of 1-10,000 mg. See, column 1, line 52 bridging column 2, line 59, column 5, lines 56-65, column 13, lines 8-9, and claim 8. Meisner teaches a method for accelerated wound healing or treating degenerative disorders including periodontal disease, osteoarthritis, comprising administering a composition comprising creatine to an animal or human. See, particularly, column 1, line 28 bridging column 2, line 45, column 5, lines 3 bridging column 7, line 10. Beale ('469) teaches creatine pyruvate (pyruvyl-creatine) is particularly useful as cortisol antagonist or cortisol blocker for prevent the catabolic activity of cortisol. See column 1, lines 7-18, 54-60; column 3, lines 46-63, and column 5, lines 54-60. Beale ('926) further teaches that pyruvate is known to be useful for treating osteoporosis. See, claim 24.

Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed the invention was made, to employ creatine pyruvate composition, for improving bone conditions, or for accelerating healing of pathogenic bone conditions, including bone implantation and defect bone caused by trauma or otherwise. Note claims 23 and 24 read

Art Unit: 1617

on the composition comprising creatine pyruvate, since creatine pyruvate is both a creatine salt, and a pyruvate.

A person of ordinary skill in the art would have been motivated to employ creatine pyruvate composition, for improving bone conditions, or for accelerating healing of pathogenic bone conditions, including bone implantation and defect bone caused by trauma or otherwise. because creatine and pyruvate, either alone, or in combinations are known to be useful for improving bone conditions. Further, it is prima facie obvious to combine two compounds each of which is taught in the prior art to be useful for same purpose in order to form third composition that is to be used for very the same purpose; idea of combining them flows logically from their having been individually taught in prior art; thus, the claimed invention which employ a combination (salt) of two compounds known to be useful for treating osteoporosis sets forth prima facie obvious subject matter. See In re Kerkhoven, 205 USPQ 1069. Note treating osteoporosis is to promoting minerization of bone. Further, creatine pyruvate is particularly known to be useful for treating disease associated with cortisol activity and connective tissue degenerative disorders is known to be closely related to cortisol activity. Finally, creatine is known to be useful for promoting tissue repair process, and treating osteoarthritis and osteoporosis would also considered as a process of promoting tissue (cartilage) repairing since one of the major symptoms of osteoarthritis and osteoporosis is tissue degeneration. Finally, The optimization of a result effective parameter, e.g., the effective amount of creatine, particularly within the range of the prior art, is considered within the skill of the artisan, absent evidence to the contrary. See, <u>In re Boesch and Slaney</u> (CCPA) 204 USPQ 215. Furthermore, the instant claims are essentially directed to a particular salt of creatine for treating disorders known to be

Art Unit: 1617

treated by creatine, or its derivatives, or its salts. Absent evidence to the contrary, the employment of pyruvate creatine is seen to be a selection from amongst equally suitable material and as such obvious. Ex parte Winters 11 USPQ 2<sup>nd</sup> 1387 (at 1388). It is well settled that in the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191USPO 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed.Cir. 1990).

## Response to the Arguments

Applicants' amendments and remarks submitted April 17, 2007 have been fully considered, but are not persuasive.

Applicants assert that since the cited references do not teach expressly the particular patient population herein required, i.e., patients with bone implant, or with bone defect caused by trauma or surgery, the claimed inventions are not obvious over the cited references. The examiner respectfully disagrees. Note the cited references as a whole teaches that creatine are useful for improving bone conditions, as evidenced by treatment of o osteoporosis, osteoarthritis or periodontitis, or for accelerating wound healing, promoting growth of connective tissue (cartilage). Therefore, one of ordinary skill in the art would have been motivated to use creatine, or its salts for treatment of bone conditions that requires improving bone conditions. Note, question under 35 U.S.C. 103 is not merely what reference expressly teach, but what they would have suggested to one of ordinary skill in the art at the time the invention was made; all disclosures of prior art, including unpreferred embodiments, must considered. In re Lamberti and Konort (CCPA), 192 USPQ 278.

Application/Control Number: 09/769,404 Page 6

Art Unit: 1617

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang whose telephone number is (571) 272-0632. The examiner can normally be reached on Monday to Friday from 7:00 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Shengjun Wang
Primary Examiner
Art Unit 1617

5 shandrunning